BRINGING NOVEL INVESTIGATIONAL TREATMENTS FOR ECZEMA, ASTHMA and cancer ONE STEP CLOSER TO APPROVAL
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
August 11, 2022
Company maintains strong cash position of $207.3 million
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter and six months ended June 30, 2022.
“Our operational momentum continued in the second quarter as we initiated our Phase 2b clinical trial of RPT193 in patients with moderate-to-severe atopic dermatitis and strengthened our balance sheet with a $50 million financing,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “As we head into the second half of the year, we expect to broaden the RPT193 program with the initiation of a Phase 2a trial in asthma and to continue advancing our FLX475 program in multiple cancer indications. We anticipate our pipeline of promising oral drugs will provide a number of significant data catalysts over the next 12 to 18 months.”
Financial Results for the Second Quarter and Six Months Ended June 30, 2022
Second Quarter Ended June 30, 2022
Net loss for the second quarter of 2022 was $19.2 million, compared to $16.1 million for the second quarter of 2021.
Research and development expenses for the second quarter of 2022 were $14.4 million, compared to $13.2 million for the same period in 2021. The increase in research and development expenses was primarily due to higher development costs related to RPT193 and increases in expenses for personnel and facilities, partially offset by decreases in development costs related to FLX475 and stock-based compensation expense.
General and administrative expenses for the second quarter of 2022 were $5.4 million, compared to $3.8 million for the same period in 2021. The increase in general and administrative expenses was primarily due to increases in expenses for professional services, personnel, stock-based compensation and facilities.
Six Months Ended June 30, 2022
Net loss for the six months ended June 30, 2022 was $39.7 million, compared to $32.6 million for the same period in 2021.
Research and development expenses for the six months ended June 30, 2022 were $31.0 million, compared to $27.0 million for the same period in 2021. The increase in research and development expenses was primarily due to higher development costs related to RPT193 and increases in expenses for early-stage programs, personnel and facilities, partially offset by decreases in development costs related to FLX475 and stock-based compensation expense.
General and administrative expenses for the six months ended June 30, 2022 were $10.2 million, compared to $7.8 million for the same period of 2021. The increase in general and administrative expenses was primarily due to increases in expenses for professional services, personnel, stock-based compensation and facilities.
As of June 30, 2022, the Company had cash, cash equivalents and marketable securities of $207.3 million, which includes net proceeds of $49.8 million from our May 2022 sale of pre-funded warrants to purchase 4.0 million shares of our common stock.
About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “could,” “expect,” “look forward,” “target,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about clinical development progress and the timing of initiation and completion of, and results from, clinical trials of RPT193 and FLX475. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, preliminary data and trends may not be predictive of future data or results, may not demonstrate safety or efficacy or lead to regulatory approval, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to the COVID-19 pandemic (along with the effects of the war in Ukraine, inflation, rising interest rates and other economic uncertainty), changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process and the sufficiency of RAPT’s cash resources. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 11, 2022 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.
RAPT Media Contact:
RAPT Investor Contact:
RAPT THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share per share data)
|Three Months Ended
|Three Months Ended
|Six Months Ended
|Six Months Ended
|Research and development||14,359||13,190||31,029||26,961|
|General and administrative||5,436||3,760||10,184||7,772|
|Total operating expenses||19,795||16,950||41,213||34,733|
|Loss from operations||(18,909||)||(16,081||)||(39,686||)||(32,642||)|
|Other income (expense), net||(275||)||(29||)||34||18|
|Other comprehensive income (loss):|
|Foreign currency translation gain||550||70||349||108|
|Unrealized loss on marketable securities||(178||)||(18||)||(888||)||(68||)|
|Total comprehensive loss||$||(18,812||)||$||(16,058||)||$||(40,191||)||$||(32,584||)|
|Net loss per share, basic and diluted||$||(0.62||)||$||(0.63||)||$||(1.31||)||$||(1.29||)|
|Weighted average number of shares used in computing
net loss per share, basic and diluted
RAPT THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
|Cash and cash equivalents||$||57,203||$||24,027|
|Prepaid expenses and other current assets||2,588||3,319|
|Total current assets||209,929||192,973|
|Property and equipment, net||2,921||2,741|
|Operating lease right-of-use assets||6,055||—|
|Liabilities and stockholders’ equity|
|Deferred revenue, current||—||1,016|
|Operating lease liabilities, current||1,503||—|
|Other current liabilities||39||254|
|Total current liabilities||13,146||9,595|
|Deferred rent, net of current portion||—||2,150|
|Deferred revenue, non-current||—||511|
|Operating lease liabilities, non-current||6,717||—|
|Additional paid-in capital||526,573||470,629|
|Accumulated other comprehensive loss||(745||)||(206||)|
|Total stockholders’ equity||202,133||186,380|
|Total liabilities and stockholders’ equity||$||221,996||$||198,636|
(1) The condensed consolidated balance sheet for December 31, 2021 has been derived from audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.
« back to news page